ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

RISING INCIDENCE OF FATTY LIVER DISEASE IN YOUNG ADULTS: EPIDEMIOLOGY, RISK FACTORS, AND PUBLIC HEALTH IMPLICATIONS

Dr. AMAN KHANDELWAL, Assistant Teacher, Samarkand state medical university, Uzbekistan, Aman3238@gmail.com

Sahibole Mohammed, medical student, Samarkand state medical university, Uzbekistan , msahibole858@gmail.com

Zunaira Khan , medical student, Samarkand state medical university, Uzbekistan zunairakhan1167@gmail.com

Keywords: *Non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), young adults, adolescents, obesity, insulin resistance, epidemiology, liver fibrosis, public health, metabolic syndrome*

1. Introduction

Non-alcoholic fatty liver disease (NAFLD), recently rebranded as metabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as one of the most pressing chronic liver conditions affecting the global population. Historically perceived as a disease of middle-aged and older adults with metabolic comorbidities, NAFLD is now increasingly diagnosed in adolescents and young adults aged 15–39 years. This demographic shift represents a significant public health concern, as early-onset hepatic steatosis provides a longer window for disease progression to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma.

The global prevalence of NAFLD has risen dramatically from approximately 25.3% during 1990–2006 to 38.0% during 2016–2019, reflecting broader changes in dietary patterns, physical activity levels, and the worldwide obesity epidemic. Among younger populations, the burden is particularly alarming. Recent analyses utilizing the Global Burden of Disease (GBD) 2021 database indicate that incident cases of NAFLD among individuals aged 15–39 years increased by 71% between 1990 and 2021, rising from 17.05 million to 29.08 million cases globally. The age-standardized incidence rate (ASIR) among the 19–35 age group escalated by 26% over this three-decade period.

This review examines the epidemiological trends, pathophysiological mechanisms, risk determinants, diagnostic approaches, and preventive strategies

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

relevant to NAFLD in young adult populations. Understanding these dimensions is essential for developing age-specific interventions that can mitigate the long-term detrimental effects of this chronic disease and reduce its growing burden on healthcare systems worldwide.

2. Epidemiology and Global Burden

2.1 Global Trends in Young Populations

The epidemiological landscape of NAFLD among youth and young adults has undergone substantial transformation over the past three decades. According to systematic analyses of the GBD 2021 study, the global burden of NAFLD in the 15–39 year age group has demonstrated a consistent upward trajectory across all 21 regions studied. The age-standardized prevalence rate (ASPR) increased by 29%, from 11,010.48 per 100,000 population in 1990 to 14,221.32 per 100,000 population in 2021, with an estimated annual percentage change (EAPC) of 0.84.

Notably, the highest incidence numbers and rates in 2021 were observed in the 15–24 year age brackets, gradually declining with advancing age within this cohort. This pattern reflects a concerning tendency toward younger onset of NAFLD, which has profound implications for cumulative lifetime disease burden. When stratified by sex, males consistently demonstrated higher incidence and prevalence rates than females across all age groups, a disparity partially attributable to the protective effects of estrogen against hepatic steatosis.

2.2 Regional and Socioeconomic Disparities

The distribution of NAFLD burden is not uniform across geographic and socioeconomic boundaries. Middle and low-middle sociodemographic index (SDI) regions have experienced particularly steep increases in prevalent cases, though high-SDI nations maintain substantial absolute numbers. In the United States, nationally representative data from the National Health and Nutrition Examination Survey (NHANES) spanning 2007–2016 revealed an overall NAFLD prevalence of 18.5% among adolescents and young adults aged 12–29 years, with marked variation across age subgroups.

12–17 (Early/Middle Adolescents)	13.2%	11.37–14.96

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

18–24 (Late Adolescents/Young Adults)	18.7%	16.2–21.2
25–29 (Older Young Adults)	24.0%	21.5–26.5
Overall (12–29)	18.5%	16.8–20.2

Table 1. Prevalence of NAFLD among adolescents and young adults in the United States by age group (NHANES 2007–2016).

Racial and ethnic disparities further complicate the epidemiological picture. Among all age groups in the U.S. cohort, Hispanic individuals demonstrated the highest prevalence of NAFLD, followed by non-Hispanic Whites and non-Hispanic Blacks. Among late adolescents aged 18–24, Hispanics exhibited a prevalence of 32.2% compared to 17.7% in Whites and 7.5% in Blacks. These differences likely reflect the intersection of genetic predisposition, dietary acculturation, socioeconomic factors, and differential access to healthcare resources.

2.3 Temporal Trends and Emerging Patterns

Perhaps the most disturbing finding from recent epidemiological surveillance is the rapid increase in NAFLD prevalence specifically among 18–24 year-olds. In the U.S. NHANES data, prevalence in this demographic rose from 10.7% during 2007–2008 to 24.8% during 2015–2016, representing a 132% increase over less than a decade. This surge was primarily driven by increases among White and Hispanic late adolescent males, coinciding with parallel rises in obesity and type 2 diabetes mellitus within this subgroup.

In contrast, NAFLD prevalence among early adolescents (12–17 years) and older young adults (25–29 years) remained relatively stable during the same observation period. The unique vulnerability of the 18–24 age group may reflect transitional life changes—including increased autonomy over food choices, irregular meal patterns, higher alcohol consumption, reduced structured physical activity, and the stress associated with higher education or early career establishment.

3. Risk Factors and Pathophysiology

3.1 Metabolic Risk Factors

The pathogenesis of NAFLD in young adults is multifactorial, involving a complex interplay between genetic susceptibility, environmental exposures, and

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

metabolic dysfunction. Obesity represents the most significant modifiable risk factor. In the NHANES cohort, although only approximately 25% of the overall study population was classified as obese, over 75% of those with NAFLD met obesity criteria. The mean body mass index (BMI) among young adults with NAFLD was 34.76 kg/m² compared to 22.09 kg/m² in those without the condition.

Insulin resistance constitutes another cornerstone of NAFLD pathophysiology. Over 93% of young individuals with NAFLD demonstrated insulin resistance as measured by HOMA-IR scores, compared to approximately 32% in the non-NAFLD group. Remarkably, the highest mean HOMA-IR values were observed in the youngest age group (12–17 years), where over 40% exhibited insulin resistance. This early metabolic dysregulation sets the stage for progressive beta-cell dysfunction and type 2 diabetes, with the prevalence of diabetes among NAFLD-affected young adults reaching 6.9%—substantially higher than the general population rate reported by the Centers for Disease Control and Prevention.

Additional metabolic comorbidities frequently co-occur with NAFLD in this population. Hyperlipidemia was present in 68.5% of affected young adults, hypertension in 19.2%, and central obesity (elevated waist circumference) in the vast majority. The clustering of these conditions within individuals underscores the systemic nature of metabolic dysfunction in early-onset NAFLD.

Obesity (BMI ≥30 kg/m²)	75.2	11.7	P < 0.0001
Insulin Resistance (HOMA-IR >2.5)	93.4	31.9	P < 0.0001
Hyperlipidemia	68.5	28.3	P < 0.0001
Hypertension	19.2	2.8	P < 0.0001
Type 2 Diabetes	6.9	0.6	P = 0.0003

Table 2. Comparison of metabolic comorbidities among adolescents and young adults with and without NAFLD (NHANES 2007–2016).

3.2 Dietary and Lifestyle Determinants

Contemporary dietary patterns among young adults have shifted dramatically toward energy-dense, nutrient-poor foods characterized by high levels of refined

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

carbohydrates, added sugars (particularly fructose), saturated fats, and ultra-processed ingredients. The consumption of sugar-sweetened beverages, fast food, and convenience meals has become normalized during the transition from adolescence to independent adulthood. Fructose, in particular, promotes hepatic de novo lipogenesis, impairs insulin signaling, and drives visceral adiposity—creating a metabolic environment highly conducive to hepatic fat accumulation.

Physical inactivity represents a parallel and equally important risk factor. The transition from structured school-based physical education to sedentary occupational and recreational patterns during young adulthood contributes significantly to positive energy balance. Screen time, including smartphones, computers, and streaming entertainment, has displaced active leisure pursuits in this demographic. Sleep disruption and circadian misalignment—common among university students and young professionals—further exacerbate metabolic dysregulation through alterations in hunger hormones, cortisol rhythms, and glucose homeostasis.

3.3 Genetic and Epigenetic Influences

While environmental factors dominate the risk profile for NAFLD, genetic susceptibility modulates individual vulnerability. Polymorphisms in genes involved in lipid metabolism, such as PNPLA3, TM6SF2, and MBOAT7, have been associated with increased hepatic fat content and progression to fibrosis across all age groups, including young adults. The higher prevalence observed among Hispanic populations may partly reflect higher frequencies of risk alleles in these genetic loci.

Epigenetic modifications—heritable changes in gene expression without alterations to the DNA sequence—may also play a role in the rising incidence of early-onset NAFLD. Maternal obesity, gestational diabetes, and early childhood nutrition can induce epigenetic programming that predisposes offspring to metabolic diseases later in life. As the obesity epidemic extends across generations, these transgenerational effects may contribute to the declining age of NAFLD onset.

[Figure 3. Protective and risk factors influencing the development and prevention of chronic liver diseases in young populations.]

4. Disease Progression and Clinical Consequences

4.1 Natural History of Early-Onset NAFLD

NAFLD exists along a disease spectrum ranging from simple steatosis (fat accumulation without significant inflammation) to non-alcoholic steatohepatitis

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

(NASH), characterized by hepatocyte injury, ballooning degeneration, and lobular inflammation. Approximately 10–20% of NAFLD patients may progress to NASH, with a subset developing advanced fibrosis, cirrhosis, and eventually hepatocellular carcinoma. The prolonged disease trajectory associated with early-onset NAFLD substantially increases the cumulative lifetime risk of these complications.

Young adults with NAFLD face decades of potential disease progression, making early intervention particularly critical. Fibrosis, once considered rare in pediatric and young adult populations, is increasingly recognized in this age group. While advanced fibrosis (FIB-4 > 2.67) was not detected in the NHANES young adult cohort—likely due to the relatively recent onset of disease in most cases—mild to moderate fibrosis may already be present in a subset of patients, particularly those with severe obesity or coexisting metabolic syndrome.

4.2 Extrahepatic Manifestations

NAFLD in young adults is not merely a hepatic condition but rather a systemic disorder with widespread implications. Cardiovascular disease represents the leading cause of mortality among NAFLD patients, and the presence of hepatic steatosis in young adulthood accelerates atherosclerotic processes. Chronic low-grade inflammation, endothelial dysfunction, and dyslipidemia contribute to premature cardiovascular morbidity.

Polycystic ovary syndrome (PCOS) and reproductive dysfunction are increasingly recognized in young women with NAFLD, mediated by shared insulin resistance and hyperandrogenism. Obstructive sleep apnea, chronic kidney disease, and certain extrahepatic malignancies also demonstrate associations with NAFLD, though long-term data specific to young adult populations remain limited.

4.3 Psychosocial Impact

The diagnosis of a chronic liver disease during young adulthood carries significant psychosocial consequences. Anxiety, depression, and reduced health-related quality of life are common among young NAFLD patients. Concerns regarding body image, dietary restrictions, long-term prognosis, and potential stigma associated with obesity and liver disease can impair social functioning, academic performance, and career development. The invisible nature of early-stage NAFLD may also lead to poor adherence to lifestyle modifications, as patients often remain asymptomatic and underestimate their disease risk.

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

[Figure 4. Comprehensive infographic illustrating symptoms, risk factors, and treatment approaches for fatty liver disease.]

5. Diagnosis and Screening

5.1 Non-Invasive Diagnostic Approaches

The diagnosis of NAFLD requires evidence of hepatic steatosis in the absence of significant alcohol consumption and other secondary causes of liver disease. In young adult populations, non-invasive methods are preferred due to accessibility, cost-effectiveness, and patient acceptability. Serum biomarker panels, including the U.S. Fatty Liver Index (US-FLI), Fatty Liver Index (FLI), and elevated alanine aminotransferase (ALT), offer reasonable accuracy for identifying steatosis in epidemiological and clinical settings.

Imaging modalities provide more direct assessment of hepatic fat. Ultrasonography, though widely available, has reduced sensitivity in patients with mild steatosis and those with obesity. Controlled attenuation parameter (CAP) obtained during transient elastography (FibroScan) quantifies liver fat content with greater precision and has been increasingly utilized in younger populations. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) represents the gold standard for non-invasive steatosis quantification but remains limited by cost and availability.

5.2 Assessment of Fibrosis

Distinguishing simple steatosis from NASH and identifying fibrosis are critical for risk stratification. However, standard non-invasive fibrosis scores such as FIB-4 and NAFLD Fibrosis Score have limited validation in individuals under 35 years of age. Novel approaches, including shear wave elastography and magnetic resonance elastography (MRE), show promise for assessing liver stiffness in younger patients, though normative data continue to evolve. Given these limitations, liver biopsy remains the definitive diagnostic tool when clinical uncertainty exists or when advanced fibrosis is suspected in young adults.

5.3 Screening Recommendations

Currently, universal screening for NAFLD in young adults is not recommended by major hepatology societies. However, targeted screening of high-risk groups—including those with obesity, type 2 diabetes, metabolic syndrome, PCOS, or family

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

history of advanced NAFLD—is supported by emerging evidence. Given the rising prevalence and the asymptomatic nature of early disease, there is growing advocacy for expanded screening in primary care and pediatric-to-adult transition clinics.

6. Prevention and Management Strategies

6.1 Lifestyle Modification

Lifestyle intervention remains the cornerstone of NAFLD management across all age groups, including young adults. Weight loss of 5–10% of total body weight has been shown to reduce hepatic steatosis, while losses exceeding 10% may induce NASH resolution and fibrosis regression. For young adults, sustainable dietary changes emphasizing whole foods, reduced added sugars, increased fiber intake, and Mediterranean dietary patterns offer the greatest promise.

Physical activity recommendations for NAFLD extend beyond weight loss to include direct metabolic benefits. Both aerobic exercise and resistance training reduce hepatic fat content independent of BMI changes, likely through improvements in insulin sensitivity, mitochondrial function, and lipid oxidation. Current guidelines recommend at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity physical activity weekly, combined with muscle-strengthening exercises.

6.2 Pharmacological Interventions

No pharmacotherapy is currently approved specifically for NAFLD in young adults. However, medications targeting underlying metabolic dysfunction—such as metformin for insulin resistance, statins for dyslipidemia, and glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes—may confer hepatic benefits. Vitamin E has demonstrated efficacy in non-diabetic adults with NASH, though its use in younger populations requires careful consideration of long-term safety. Several promising agents targeting fibrogenesis, inflammation, and metabolic pathways are in advanced clinical trials.

6.3 Public Health and Policy Interventions

Addressing the rising incidence of NAFLD in young adults necessitates population-level interventions beyond individual clinical care. School-based nutrition programs, sugar-sweetened beverage taxation, urban planning that promotes active transportation, and regulation of food marketing to adolescents represent evidence-based policy levers. The food environment in educational institutions and workplaces

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

warrants particular attention, as young adults frequently consume meals in these settings.

Healthcare systems must also adapt to the growing burden of young adult NAFLD through enhanced provider education, development of age-appropriate transition protocols from pediatric to adult care, and integration of hepatology services within primary care and endocrinology practices. Early identification and intervention during the young adult period offer the greatest potential for preventing progressive liver disease and its systemic complications.

Key Public Health Recommendations:

• Improve immediate food environments in schools and residential areas to ensure healthy, affordable food choices

• Increase structured physical activity options tailored to young adult preferences

• Provide comprehensive education to stakeholders regarding obesity complications, including NAFLD

• Develop culturally sensitive interventions addressing racial and ethnic disparities in NAFLD prevalence

• Implement targeted screening programs for high-risk young adult populations

7. Future Projections and Research Directions

Bayesian age-period-cohort modeling projections based on GBD 2021 data indicate that the global prevalence and disease burden of NAFLD among 15–39 year-olds will continue to increase through 2035 if current trends persist. This trajectory is attributable to multiple converging factors: ongoing lifestyle alterations, rising prevalence of metabolic diseases, uneven development of medical resources, and persistent genetic susceptibility within populations.

Future research priorities include the development and validation of non-invasive fibrosis assessment tools specifically calibrated for individuals under 35 years of age; longitudinal studies tracking the natural history of childhood and young adult NAFLD into middle and older age; investigation of sex-specific disease mechanisms and therapeutic responses; and evaluation of digital health interventions, including mobile applications and wearable devices, for promoting sustainable lifestyle change in young adult populations.

The potential impact of emerging pharmacotherapies on young adult NAFLD remains an active area of investigation. As treatments for NASH and fibrosis become

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

available, determining the optimal timing of intervention—particularly in young patients with early-stage disease—will require careful cost-effectiveness and risk-benefit analyses.

8. Conclusion

The rising incidence of fatty liver disease among young adults represents a silent epidemic with profound implications for individual health trajectories and healthcare system sustainability. Over the past three decades, global incident cases among individuals aged 15–39 years have increased by 71%, with the highest burden now observed in the 15–24 year age group. In the United States, nearly one in five adolescents and young adults is affected, with prevalence reaching 24.8% among 18–24 year-olds by 2016—a 132% increase in less than a decade.

This demographic shift is driven by the intersection of obesogenic environments, sedentary lifestyles, genetic susceptibility, and early metabolic dysfunction. The prolonged disease duration associated with young adult-onset NAFLD substantially increases lifetime risks of cirrhosis, hepatocellular carcinoma, cardiovascular disease, and extrahepatic complications. Yet the asymptomatic nature of early disease and the lack of established screening protocols mean that many affected young adults remain undiagnosed until advanced stages.

Addressing this challenge requires a multifaceted approach encompassing individual lifestyle interventions, healthcare system adaptations, and bold public health policies. Weight management, dietary modification, and increased physical activity remain the foundation of both prevention and treatment. However, without systemic changes to food environments, physical activity infrastructure, and health equity, individual-level interventions will prove insufficient to reverse current trends.

The window for action is narrowing. As the first generation to experience such high rates of early-onset metabolic liver disease reaches middle age, the consequences for liver transplantation demand, healthcare costs, and premature mortality will become increasingly apparent. Prioritizing NAFLD prevention and early intervention in young adult populations is not merely a clinical imperative but a societal necessity that demands coordinated action across healthcare, education, urban planning, and policy sectors.

References

1. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861.

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025
2. Global, regional, and national burden of NAFLD in youths and young adults aged 15–39 years, 1990–2021, its attributable risk factors, and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021. Front Public Health. 2025;13.

3. Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-2817.

4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.

5. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr. 2013;162(3):496-500.

6. Kanwal F, Shubrook JH, Adams LA, et al. Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007–2016. Hepatol Commun. 2021;5(11):1977-1989.

7. Younossi ZM, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748-755.

8. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209.

9. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.

10. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319-334.

11. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.

12. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol. 2014;5(4):277-286.

13. Romano AD, Serviddio G, de Matthaeis A, Bellanti F, Vendemiale G. Oxidative stress and aging. J Nephrol. 2010;23(Suppl 15):S29-S36.

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025
14. Della Corte C, Mosca A, Maiorani N, et al. Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: The results of an Italian Study. Nutrients. 2017;9(8):770.
15. Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119-132.